INVESTOR RELATIONS

Events & Presentations

Our Clinical Development Programs

Our pipeline provides an overview of our late-stage clinical development programs and is updated quaterly.

Explore our pipeline
  • 12 PHASE II PROGRAMS
    • MK-8521 – Diabetes Mellitus
    • MK-8591 - HIV-1 Infection
    • MK-8189 – Schizophrenia
    • CAVATAK® (V-937) – Melanoma
    • MK-7690 – Colorectal Cancer
    • KEYTRUDA® (MK-3475) – Advanced Solid Tumors
    • KEYTRUDA® (MK-3475) – Prostate Cancer
    • LENVIMA® (MK-7902) – Biliary Tract Cancer
    • LYNPARZA® (MK-7339) – Advanced Solid Tumors
    • selumetinib (MK-5618) – Pediatric Neurofibromatosis Type-1
    • MK-1654 – Respiratory Syncytial Virus
    • V160 – Cytomegalovirus Vaccine
  • 20 PHASE III PROGRAMS
    • vericiguat (MK-1242) – Heart Failure
    • SIVEXTRO® (MK-1986) – HABP/VABP – Bacterial Pneumonia
    • KEYTRUDA® (MK-3475) – Breast Cancer
    • KEYTRUDA® – (MK-3475) (EU) – Cervical Cancer
    • KEYTRUDA® – (MK-3475) – Colorectal Cancer
    • KEYTRUDA® – (MK-3475) – Cutaneous Squamous Cell Carcinoma
    • KEYTRUDA® – (MK-3475) – Esophageal Cancer
    • KEYTRUDA® – (MK-3475) (EU) – Gastric Cancer
    • KEYTRUDA® – (MK-3475) (EU) – Liver Cancer
    • KEYTRUDA® – (MK-3475) – Mesothelioma
    • KEYTRUDA® – (MK-3475) – Nasopharyngeal Cancer
    • KEYTRUDA® – (MK-3475) (EU) – Ovarian Cancer
    • KEYTRUDA® – (MK-3475) (EU) – Small Cell Lung Cancer
    • LENVIMA® – (MK-7902) – Endometrial Cancer
    • LENVIMA® – (MK-7902) – Melanoma
    • LENVIMA® – (MK-7902) – Non-Small Cell Lung Cancer
    • LYNPARZA® (MK-7339) – Pancreatic Cancer
    • LYNPARZA® (MK-7339) – Prostate Cancer
    • gefapixant (MK-7264) – Cough
    • V114 – Pneumoconjugate Vaccine
  • 2 UNDER REVIEW
    • relebactam + imipenem + cilastatin (MK-7655A) (US, EU) – Bacterial Infection
    • V920 (US, EU) – Ebola Vaccine
  • MK-8521 – Diabetes Mellitus
  • MK-8591 - HIV-1 Infection
  • MK-8189 – Schizophrenia
  • CAVATAK® (V-937) – Melanoma
  • MK-7690 – Colorectal Cancer
  • KEYTRUDA® (MK-3475) – Advanced Solid Tumors
  • KEYTRUDA® (MK-3475) – Prostate Cancer
  • LENVIMA® (MK-7902) – Biliary Tract Cancer
  • LYNPARZA® (MK-7339) – Advanced Solid Tumors
  • selumetinib (MK-5618) – Pediatric Neurofibromatosis Type-1
  • MK-1654 – Respiratory Syncytial Virus
  • V160 – Cytomegalovirus Vaccine
  • vericiguat (MK-1242) – Heart Failure
  • SIVEXTRO® (MK-1986) – HABP/VABP – Bacterial Pneumonia
  • KEYTRUDA® (MK-3475) – Breast Cancer
  • KEYTRUDA® – (MK-3475) (EU) – Cervical Cancer
  • KEYTRUDA® – (MK-3475) – Colorectal Cancer
  • KEYTRUDA® – (MK-3475) – Cutaneous Squamous Cell Carcinoma
  • KEYTRUDA® – (MK-3475) – Esophageal Cancer
  • KEYTRUDA® – (MK-3475) (EU) – Gastric Cancer
  • KEYTRUDA® – (MK-3475) (EU) – Liver Cancer
  • KEYTRUDA® – (MK-3475) – Mesothelioma
  • KEYTRUDA® – (MK-3475) – Nasopharyngeal Cancer
  • KEYTRUDA® – (MK-3475) (EU) – Ovarian Cancer
  • KEYTRUDA® – (MK-3475) (EU) – Small Cell Lung Cancer
  • LENVIMA® – (MK-7902) – Endometrial Cancer
  • LENVIMA® – (MK-7902) – Melanoma
  • LENVIMA® – (MK-7902) – Non-Small Cell Lung Cancer
  • LYNPARZA® (MK-7339) – Pancreatic Cancer
  • LYNPARZA® (MK-7339) – Prostate Cancer
  • gefapixant (MK-7264) – Cough
  • V114 – Pneumoconjugate Vaccine
  • relebactam + imipenem + cilastatin (MK-7655A) (US, EU) – Bacterial Infection
  • V920 (US, EU) – Ebola Vaccine
Data as of May 1, 2019